Signals That Will Matter Beyond the Conference
Each January, the J.P. Morgan Annual Healthcare Conference offers a rare moment of signal clarity. Management teams, investors, strategics, and advisors converge not just to reflect on the year behind us, but to quietly recalibrate expectations for the year ahead.
In a market still defined by selectivity, valuation dispersion, and heightened scrutiny around execution, JPM 2026 is unlikely to be about broad sector enthusiasm. Instead, we expect conversations to center on proof, durability, and discipline, with investors listening closely for signals that extend well beyond a single conference week.
Below, we outline what we (and investors) are watching by sector, and what management teams should be prepared to articulate clearly as meetings begin.
Biotech: From Optionality to Credibility
For biotech, the tone heading into JPM 2026 remains cautious, but more constructive than a year ago. Capital remains available, but it is highly conditional, with investors rewarding clarity of path over breadth of ambition.
What investors are listening for:
- Clinical prioritization: A continued shift away from “platform sprawl” toward tightly sequenced development plans with clear capital efficiency.
- Regulatory realism: Evidence that teams understand not just regulatory milestones, but regulatory risk, timing, and potential friction points.
- Financing foresight: Early acknowledgement of capital needs and funding strategy—rather than reactive messaging after the fact.
- Strategic interest signals: Even absent transactions, language that demonstrates awareness of where assets fit within larger pharma portfolios.
IR Implications
Biotech stories that resonate at JPM will be those that reduce uncertainty, not amplify upside. Clear use-of-capital narratives, realistic timelines, and disciplined messaging around value inflection points are likely to carry more weight than expansive vision statements.
Medtech: Growth, Resilience, and Scale
In medtech, the conversation entering 2026 feels centered– as always – around innovation novelty. But in addition, investors are focused on commercial durability and operational strength more than ever. Funds are looking to understand whether companies in their coverage universe can demonstrate growth that is structurally supported vs. simply benefitting from short-term product cycles, procedure trends, or pricing dynamics.
What investors are listening for:
- Procedure normalization: Realistic framing of today’s procedure volumes and sustainable growth rates.
- Product vs. portfolio clarity: A sharper lens on which product lines will truly drive long-term value, in addition to a holistic view of business performance and, if applicable, the benefits of your complete suite of solutions together.
- Operational resilience: Evidence that supply chains, manufacturing, and quality systems can support scale without margin erosion – and ideally, while expanding margins.
- Specific catalysts ahead: Whether these are clinical, regulatory, commercial, or financial – provide a clear roadmap to upcoming milestones with achievable timelines.
IR Implications
Medtech companies that can clearly articulate their drivers of growth and operational strategies, as well as potential upside opportunities and risks to manage, should be rewarded throughout the year. Historically, strong management teams have anchored their stories with repeatability and predictability.
Life Science Tools & Diagnostics: Differentiation in a Crowded Field
Tools and diagnostics companies enter JPM 2026 against a backdrop of ongoing consolidation and intensifying competition. Investors are increasingly selective, looking for defensible differentiation rather than incremental product expansion.
What investors are listening for:
- Customer value articulation: How clearly teams can explain why their tools matter operationally—not just technically.
- Revenue quality: Emphasis on recurring revenue, workflow integration, and customer stickiness.
- Clinical and economic proof: For diagnostics, stronger linkage between clinical utility and economic decision-making.
- M&A readiness: Whether teams can speak credibly about integration, scalability, and strategic fit—regardless of near-term deal intentions.
IR Implications
The strongest narratives in tools and diagnostics tend to move beyond feature sets and into systems thinking – how products fit into broader lab, clinical, or data ecosystems, and why that positioning is difficult to displace.
Healthcare Services & Healthcare IT: Execution Over Vision
Healthcare services and HCIT companies arrive at JPM facing a more pragmatic investor audience. Growth stories remain attractive, but only when paired with evidence of operational control and unit economics.
What investors are listening for:
- Margin discipline: Clear paths to sustainable profitability or reinvestment efficiency.
- Technology enablement: For HCIT, concrete proof that platforms drive measurable outcomes, not just workflow change.
- Regulatory and policy fluency: Awareness of how reimbursement, labor dynamics, and compliance shape scalability.
- Integration capability: Especially for acquisitive models, clarity on how systems, cultures, and data are unified.
IR Implications
Investors are increasingly wary of abstract transformation narratives. Companies that succeed will ground their stories in execution metrics, customer outcomes, and operational transparency.
A Common Thread Across Sectors: Fewer Promises, Better Signals
Across biotech, medtech, tools and diagnostics, and services, one theme appears consistent heading into JPM 2026: investors are rewarding signal quality over story volume.
That means:
- Tighter messaging
- More explicit acknowledgment of risk
- Earlier communication around capital strategy
- Fewer surprises (and fewer superlatives)
For management teams, JPM remains a critical moment not to sell the future, but to establish credibility for the future.
In Conclusion
The most effective JPM conversations rarely hinge on a single announcement. Instead, they are built on consistency between strategy and execution, between narrative and numbers, and between ambition and discipline.
As the healthcare community convenes in San Francisco, we’ll be listening closely for those signals.
Gilmartin has extensive experience helping healthcare companies prepare for JPM and engage effectively with the investment community after the conference. Reach out to our team to learn more about how we partner with clients to sharpen messaging, position strategy, and navigate capital markets conversations at critical moments.